RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @drmkmittal: 🙏PRAGUE-18, Prasugrel=Ticagrelor for efficacy 1yr after MI. 💲motivated switch 2 plavix post DC, similar ischemic events. Ve…
RT @drmkmittal: 🙏PRAGUE-18, Prasugrel=Ticagrelor for efficacy 1yr after MI. 💲motivated switch 2 plavix post DC, similar ischemic events. Ve…
RT @drmkmittal: 🙏PRAGUE-18, Prasugrel=Ticagrelor for efficacy 1yr after MI. 💲motivated switch 2 plavix post DC, similar ischemic events. Ve…
【PRAGUE-18試験1年観察データ:PCI施行AMI例に対するプラスグレル群とチカグレロル群の転帰に有意差なし】 https://t.co/TziARfliLA JACC
RT @drmkmittal: 🙏PRAGUE-18, Prasugrel=Ticagrelor for efficacy 1yr after MI. 💲motivated switch 2 plavix post DC, similar ischemic events. Ve…
PRAGUE-18: PRASUGREL=TICAGRELOR for early MI outcomes, do u have a preffered DAPT strategy for CTO intervention @esbrilakis @manesh_patelMD @rwyeh @DLBHATTMD @KAlaswadMD @CRT_meeting #CTO https://t.co/fLPaXN04wj
🙏PRAGUE-18, Prasugrel=Ticagrelor for efficacy 1yr after MI. 💲motivated switch 2 plavix post DC, similar ischemic events. Very helpful for practicing cardiologist, specially since Effient is generic! @DrMarthaGulati @SVRaoMD https://t.co/fLPaXN04wj
"Economically motivated early post-discharge switches to clopidogrel were not associated with an increased risk of ischemic events." @PittCardiology https://t.co/vo5PneZCZ6
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
Clinical trial with many methodological problems. Better a pragmatic trial? https://t.co/VfJC8LMPVh
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor https://t.co/XJJ3Xi6bub
Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their value? Are the hypotheses they generate better then those from observational data? To add to other underpowered trials in meta-analys
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @rafasadaba: Prasugrel and ticagrelor appear to be similarly effective during the first year following a myocardial infarction. https://…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @rafasadaba: Prasugrel and ticagrelor appear to be similarly effective during the first year following a myocardial infarction. https://…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
Interesting to see no difference w tica vs prasugrel in ACS as per ITT. However results hard to interpret w so many pts switching to cheaper clopidogrel https://t.co/YvqETTrhLh
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
Prasugrel and ticagrelor appear to be similarly effective during the first year following a myocardial infarction. https://t.co/knLlkq1sgc
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3 https://t.co/Hd1sdUsTZ8
In STEMI treated with PCI outcomes does not differ between newer antiplatelet medications, and patients who switch to clopidogrel for economic reasons. https://t.co/1gvOjYYqoP
One-year Outcomes of Prasugrel Versus Ticagrelor In Acute Myocardial Infarction Treated With Primary Angioplasty: The PRAGUE-18 Study. https://t.co/uSQl71VSMg
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @jsenior64: One-year Outcomes of Prasugrel Versus Ticagrelor In Acute Myocardial Infarction Treated With Primary Angioplasty: The PRAGUE…
One-year Outcomes of Prasugrel Versus Ticagrelor In Acute Myocardial Infarction Treated With Primary Angioplasty: The PRAGUE-18 Study https://t.co/HmBoWXC8T1 TOPIC trial https://t.co/948zqZLyO8 https://t.co/qSnwerlN5v
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
#AHA17 One-year Outcomes of Prasugrel Versus Ticagrelor In Acute Myocardial Infarction Treated With Primary Angioplasty: The PRAGUE-18 Study https://t.co/lKxtisDN8R
#STEMI https://t.co/pWc3UcZbu8 Vía ACCinTouch
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
Prasugrel = Ticagrelor effective during 1y after MI. Economically motivated early post-discharge switches to clopidogrel were not associated with an increased risk of ischemic events. PRAGUE18 @secardiologia https://t.co/NAfAd1EyOE
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
RT @JACCJournals: #AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first ye…
#AHA17 Late-breaker in #JACC: #prasugrel and #ticagrelor are equally safe and effective in STEMI patients within first year after heart attack in PRAGUE 18. https://t.co/Fv1RQlcfg5 @UniKarlova https://t.co/6Z9AEmAzMF
AHA 【PRAGUE-18スタディ1年観察:PCI施行MI例のCV死・MI・脳卒中抑制作用は、プラスグレルとチカグレロルに差なし。経済的理由で中途クロピドグレル切替例では、大出血、虚血イベントとも減少】 JACC https://t.co/XM7K7M97Vw